Radiation plus hormone therapy for intermediate risk prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests combining radiation therapy with two hormone-blocking drugs (darolutamide and degarelix) to treat intermediate-risk prostate cancer. The goal is to see if this combination is more effective and safe than radiation alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and male.
- You have been diagnosed with early-stage (intermediate risk) prostate cancer within the last 6 months, with a PSA level between 10 and 20 and/or a Gleason score of 7.
- You have not received hormone therapy (like Lupron, Zoladex, or similar) in the past 12 months, nor any chemotherapy for prostate cancer.
- Your liver and kidney function are within acceptable levels, and you are generally able to be up and about for at least part of the day.
- You agree to use reliable birth control if you are sexually active with a woman who could become pregnant, for the duration of the study and for 4 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding darolutamide to standard radiation can better control intermediate-risk prostate cancer. It includes men whose cancer has spread nowhere else and who are newly diagnosed with “unfavorable intermediate risk” or progress to that risk group.
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
This Phase 3 trial compares two treatment approaches: stereotactic radiation therapy by itself versus the same radiation plus hormone therapy (ADT). It aims to see which plan works better for men with higher-risk prostate cancer without spread to lymph nodes or distant sites.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.